Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Risk and Volatility
Marker Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.
Profitability
This table compares Marker Therapeutics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
| Monte Rosa Therapeutics | -186.24% | -30.14% | -20.35% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Marker Therapeutics and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Marker Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
Marker Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 986.96%. Monte Rosa Therapeutics has a consensus target price of $26.44, indicating a potential upside of 191.95%. Given Marker Therapeutics’ higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Monte Rosa Therapeutics.
Insider & Institutional Ownership
22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Marker Therapeutics and Monte Rosa Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Marker Therapeutics | $3.55 million | 4.32 | -$12.16 million | ($0.41) | -2.24 |
| Monte Rosa Therapeutics | $123.67 million | 6.26 | -$38.63 million | ($1.40) | -6.47 |
Marker Therapeutics has higher earnings, but lower revenue than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Monte Rosa Therapeutics beats Marker Therapeutics on 7 of the 13 factors compared between the two stocks.
About Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors. The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
